



WKN: A2GS5D ISIN: DE000A2GS5D8 Land: Deutschland

Nachricht vom 30.07.2022 | 20:22

## Dermapharm Holding SE: binding offer to acquire Arkopharma Group

Dermapharm Holding SE / Key word(s): Takeover  
Dermapharm Holding SE: binding offer to acquire Arkopharma Group

30-Jul-2022 / 20:22 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

---

**Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) No. 596/2014 on market abuse, as amended (Market Abuse Regulation - MAR)**

### *Dermapharm Holding SE: binding offer to acquire Arkopharma Group*

Grünwald, July 30, 2022 - Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), offered to acquire 100% of the shares in Aphaarma TopCo SAS, headquartered in Carros, France, from private equity firm Montagu and minority shareholders of the target, for a purchase price approximating EUR 450 million.

Aphaarma TopCo SAS is the holding company of the Arkopharma Group, a provider of herbal OTC products and dietary supplements in France and other European countries. In the financial year 2021, Arkopharma Group achieved sales of approximately EUR 191 million. For the current financial year 2022, it forecasts sales of slightly over EUR 200 million.

The execution of the corresponding share purchase agreement is subject to the consultation of the works council of certain French companies of the Arkopharma Group. The Management Board expects the transaction to be completed at the beginning of January 2023.

>End of the Ad hoc announcement <

### Contact

Investor Relations & Corporate Communications  
Britta Hamberger  
Phone: +49 (0)89 - 64186-233  
E-Mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)

---

30-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  
Archive at [www.dgap.de](http://www.dgap.de)

---

Language: English  
Company: Dermapharm Holding SE  
Lil-Dagover-Ring 7  
82031 Grünwald  
Germany  
Phone: +49 (0)89 64 86-0  
E-mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)  
Internet: [ir.dermapharm.de](http://ir.dermapharm.de)  
ISIN: DE000A2GS5D8  
WKN: A2GS5D  
Indices: SDAX  
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in

Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange  
EQS News ID: 1409691

End of Announcement

DGAP News Service